Polar Capital Holdings Plc Grows Stake in Insmed Incorporated (NASDAQ:INSM)

Polar Capital Holdings Plc boosted its position in shares of Insmed Incorporated (NASDAQ:INSM) by 7.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 730,000 shares of the biopharmaceutical company’s stock after acquiring an additional 50,000 shares during the quarter. Polar Capital Holdings Plc’s holdings in Insmed were worth $50,399,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of INSM. Steward Partners Investment Advisory LLC lifted its stake in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC increased its holdings in Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 248 shares during the last quarter. Spire Wealth Management bought a new position in Insmed in the fourth quarter worth approximately $47,000. Smartleaf Asset Management LLC boosted its stake in shares of Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 411 shares during the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in shares of Insmed during the 4th quarter valued at $86,000.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Wells Fargo & Company upped their price target on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Morgan Stanley increased their price target on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. Stifel Nicolaus dropped their target price on shares of Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research report on Friday, February 21st. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $100.00 price objective on shares of Insmed in a research note on Wednesday, March 19th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and a consensus price target of $94.63.

Insider Transactions at Insmed

In other news, CFO Sara Bonstein sold 18,322 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total value of $1,471,439.82. Following the completion of the transaction, the chief financial officer now directly owns 118,863 shares in the company, valued at approximately $9,545,887.53. This represents a 13.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William Lewis sold 6,830 shares of the company’s stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $72.57, for a total transaction of $495,653.10. Following the completion of the transaction, the chief executive officer now directly owns 233,924 shares of the company’s stock, valued at approximately $16,975,864.68. The trade was a 2.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 88,232 shares of company stock worth $6,868,473 in the last three months. 3.00% of the stock is currently owned by company insiders.

Insmed Stock Down 0.2%

Shares of NASDAQ:INSM opened at $65.61 on Thursday. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $11.93 billion, a P/E ratio of -11.74 and a beta of 0.84. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The stock’s fifty day simple moving average is $71.99 and its 200-day simple moving average is $73.21.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The business had revenue of $92.82 million during the quarter, compared to analysts’ expectations of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Insmed’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.06) EPS. As a group, equities research analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.